Convert your FHIR JSON -> XML and back here. The CDA Book is sometimes listed for Kindle here and it is also SHIPPING from Amazon! See here for Errata.

Tuesday, October 12, 2010

Ranking Interoperability


I always appreciate it when important ideas can be communicated in easy to understand ways.  One of my colleagues recently did that in a way that impressed me over dinner at the HL7 Working Group Meeting last week.  Scott Bolte describes, using the lens of "Healthcare Economics," a method to evaluate interoperability opportunities rather concisely.  

My own post on Scope and Focus was written shortly after our conversation, and I had asked Scott for help putting together a more detailed post on his topic for this blog.  I think after you read what he has to say, you will see how the two pieces are tied together. 

Scott sent me his bullet points on the conversation via e-mail, and it was so simply written, yet easily understood that I post it below without change.  Here are his words:

How to compare interoperability opportunities...
  1. high disease penetration in a population.
  2. high societal cost burden.
  3. highly motivated patients.
  4. there is a meaningful intervention.
  5. opportunity to improve situation with improved interoperability.
#1 makes sure healthcare providers will see the condition often enough to invest their time and money adopting any improved capabilities.

#2 improves the odds that payors will reimburse.

#3 is critical to healthcare provider engagement.

#4 means there is a chance to move the dial.

#5 is actually a fill-in-the-blank. The first four can be used to assess any opportunity, but in this case it's to determine if improved interoperability is worth pursuing.

People who are worried that going after only the big hitting diseases does a disservice to rare conditions should be reassured that once the improved interoperability is working, it will benefit all similar scenarios.